• 

  Approved Covalent Drug Mechanisms

  By Dennis Hu It’s hard not to think about infectious diseases at the moment, but it’s a great time to review the drug discovery literature. One area of drug discovery that has deep roots in infectious disease research is targeted covalent inhibition. Targeted covalent inhibitors form covalent bonds with discrete targets (as opposed to non-specific…

• 

  2019 Large Molecule Drug Approvals

  2019 was another big year for novel drug approvals (48 in total) though it wasn’t the record year of 2018 (with 59). The overall explosion in biologic drugs / non-small molecule modalities continued with year with 14 novel biologic drugs, including 3 monoclonal antibodies, a recombinant fusion protein (Reblozyl), 3 ADCs, an siRNA drug (Givlaari),…

• 

  2019 Small Molecule Drug Approvals

  2019 was another big year for drug discovery, with 29 FDA novel drug approvals for small molecules (including istradefylline which was first approved in Japan, but not including brilliant blue G, fluorodopa F18, Ga-68-DOTATOC, bremelanotide, afamelanotide, and ferric maltol, which could all be considered small molecules by some definitions) and 3 for antibody-drug-conjugates so far.…

• 

  Drug Discovery Websites and Databases

  This table contains a list of some of the best drug discovery websites, online databases, and other online resources for drug hunters. If you have a suggestion that we’ve missed, feel free to reach out to info@drughunter.com. Explore drughunter.com for more drug discovery resources.

• 

  Kinase Inhibitor Types Predicted with Machine-Learning

  By Cyril Bucher You’ve probably lived this story before: you’re working on your favorite kinase, YFK1, and are looking for selective inhibitors over YFK2.  The problem is, they’re virtually identical near the active site, save for a single residue sitting in the back pocket that your amazing structural biologist has identified.  The team thinks you…

• 

  2018 Drug Approvals

  Of the record 59 FDA drug approvals from 2018, the majority were small molecules (64%). Keep at it, chemists! 🙂 Oncology and infectious diseases were the areas with most small molecule approvals, followed by genetic/rare diseases. Some more statistics below. Last year the FDA approved a record 59 novel drugs, which included 38 small molecule…